SecBot SecBot
SECBOTREPLAY Home › Report › PVLA

PVLA · Palvella Therapeutics reported full-year 2025 financial results and…

Palvella Therapeutics Inc. · PRESS-RELEASE filed Mar 31, 2026 at 07:30 ET

At the news

BULLISHIMPACT 8/10

PRESS-RELEASE filed Mar 31, 2026 at 07:30 ET

Palvella Therapeutics reported full-year 2025 financial results and provided a significant corporate update highlighting positive Phase 3 data for QTORIN™ rapamycin in microcystic lymphatic malformations, a $230 million equity raise, and an expanded clinical pipeline. The company is on track for an NDA submission in 2026 and a potential U.S. launch in 2027, positioning QTORIN™ as a first-in-class therapy for a rare disease with no approved treatments.

  • Positive Phase 3 SELVA trial results for QTORIN™ rapamycin in microcystic LMs: met primary endpoint with p<0.001, 95% of patients improved, and no drug-related serious adverse events.
  • Raised $230.0 million in gross proceeds via an oversubscribed equity offering in February 2026, bringing pro forma cash to $274 million as of December 31, 2025.
  • NDA submission for QTORIN™ rapamycin in microcystic LMs on track for second half of 2026, with potential FDA approval in first half of 2027.
  • Initiation of Phase 3 trial for cutaneous venous malformations and Phase 2 trials for angiokeratomas and DSAP all planned between Q2–H2 2026.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access